Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

16.0%

4 terminated/withdrawn out of 25 trials

Success Rate

81.8%

-4.7% vs industry average

Late-Stage Pipeline

12%

3 trials in Phase 3/4

Results Transparency

56%

10 of 18 completed trials have results

Key Signals

2 recruiting10 with results

Enrollment Performance

Analytics

Phase 1

12(50.0%)

Phase 2

9(37.5%)

Phase 3

3(12.5%)

24Total

Phase 1(12)

Phase 2(9)

Phase 3(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (25)

Showing 20 of 25 trials

NCT07387367Phase 3Recruiting

A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT

Role: lead

NCT06761677Phase 1Suspended

A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma

Role: lead

NCT05511779Phase 2Terminated

Study to Confirm of the Safety and Tolerability of Brincidofovir in Subjects With BK Virus Infection (Viremia) After Kidney Transplantation

Role: lead

NCT04706923Phase 2Recruiting

A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection

Role: lead

NCT03900377Phase 1Completed

Phase I/II Study of SyB L-0501RI in Combination With Rituximab to Treat Lymphoma

Role: lead

NCT04354402Completed

Follow-up Study of SyB L-0501 in Combination With Rituximab to Treat DLBCL

Role: lead

NCT03372837Phase 3Completed

Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell Lymphoma

Role: lead

NCT02014051Phase 1Completed

Safety and Pharmacokinetics Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS)

Role: lead

NCT01700335Phase 1Completed

Safety and Pharmacokinetics Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS)

Role: lead

NCT03005899Phase 3Terminated

Study of SyB P-1501 (Fentanyl HCI) for Treatment of Postoperative Pain

Role: lead

NCT02783547Phase 1Withdrawn

Combination Therapy of SyB C-1101 and Azacytidine in Patients With Myelodysplastic Syndrome

Role: lead

NCT03495167Phase 1Completed

Study of SyB C-1101 in Patients With Myelodysplastic Syndrome

Role: lead

NCT00794638Phase 1Completed

A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma

Role: lead

NCT03604679Phase 1Completed

SyB C-0501(Oral Bendamustine) in Patients With Advanced Solid Tumors

Role: lead

NCT04542252Phase 1Completed

Drug-Drug Interaction Study of Intravenous Administration of SyB V-1901 and Cyclosporine in Japanese Healthy Subjects

Role: lead

NCT00389051Phase 1Completed

A Phase I Study of Bendamustine Hydrochloride in Patients With Indolent B-cell Non-Hodgkin's Lymphoma

Role: lead

NCT02000154Phase 1Completed

Long Term Safety Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study

Role: lead

NCT02002936Phase 1Completed

Long Term Safety Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study

Role: lead

NCT02042911Phase 2Completed

Efficacy and Safety Study of SyB L-0501 for Patients With Chronic Lymphocytic Leukemia

Role: lead

NCT01718691Phase 2Completed

Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma

Role: lead